Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events

BACKGROUND: Immune checkpoint inhibitors (ICI) have demonstrated remarkable efficacy as cancer therapeutics, however, their use remains limited due to the development of immune related adverse events (irAEs). Immune related enterocolitis (irEC) is among the most common severe irAEs leading to the di...

Descripción completa

Detalles Bibliográficos
Autores principales: Badran, Yousef R., Cohen, Justine V., Brastianos, Priscilla K., Parikh, Aparna R., Hong, Theodore S., Dougan, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704680/
https://www.ncbi.nlm.nih.gov/pubmed/31439050
http://dx.doi.org/10.1186/s40425-019-0711-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704680/
https://www.ncbi.nlm.nih.gov/pubmed/31439050
http://dx.doi.org/10.1186/s40425-019-0711-0

Ejemplares similares